New research reveals that people who come off new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end conventional lifestyle programs.
Findings released in a leading health publication demonstrates that while overweight individuals frequently drop about a fifth of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"People buying these treatments should be informed of the potential of quick weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about 18 months.
Comparing Therapies
The research, which looked at dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who lose weight through dieting typically see a slower weight regain—around 100 grams monthly—once they finish.
Understanding the Rapid Regain
Experts believe the mechanism of the drugs explains the heightened rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone levels far above than the body's typical production might result in the system to produce less of its own natural hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement results in hunger is uncontrolled, making binge eating much more probable."
A Chronic Condition?
Health authorities suggest the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals contend that, given the significant potential of relapse, the treatment is often life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "emphasize the long-term character of excess weight," similar to managing conditions like diabetes.
User Experiences
People who have stopped the jabs describe a intense return of hunger.
"It was like something that goes on and you become ravenous," recalled a patient.
This difficulty is exacerbated if users have not adopted lasting lifestyle or habit modifications during therapy.
Widespread Interest
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while these medications are powerful agents for weight loss, they are not a standalone solution and maintained weight loss likely depends on integrated lifestyle support.
